Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia von Stein, Eytan M., DiNardo, Courtney D., Pollyea, Daniel A., Fathi, Amir T., Roboz, Gail J., Altman, Jessica K., Stone, Richard M., DeAngelo, Daniel J., Levine, Ross L., Flinn, Ian W., Kantarjian, Hagop M., Collins, Robert, Patel, Manish R., Frankel, Arthur E., Stein, Anthony, Sekeres, Mikkael A., Swords, Ronan T., Medeiros, Bruno C., Willekens, Christophe, Vyas, Paresh, Tosolini, Alessandra, Xu, Qiang, Knight, Robert D., Yen, Katharine E., Agresta, Sam, de Botton, Stephane, Tallman, Martin S.

Volltext

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia von Pollyea, Daniel A., Tallman, Martin S., de Botton, Stéphane, Kantarjian, Hagop M., Collins, Robert, Stein, Anthony S., Frattini, Mark G., Xu, Qiang, Tosolini, Alessandra, See, Wendy L., MacBeth, Kyle J., Agresta, Samuel V., Attar, Eyal C., DiNardo, Courtney D., Stein, Eytan M.

Volltext

Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition von Harding, James J, Lowery, Maeve A, Shih, Alan H, Schvartzman, Juan M, Hou, Shengqi, Famulare, Christopher, Patel, Minal, Roshal, Mikhail, Do, Richard K, Zehir, Ahmet, You, Daoqi, Selcuklu, S Duygu, Viale, Agnes, Tallman, Martin S, Hyman, David M, Reznik, Ed, Finley, Lydia W S, Papaemmanuil, Elli, Tosolini, Alessandra, Frattini, Mark G, MacBeth, Kyle J, Liu, Guowen, Fan, Bin, Choe, Sung, Wu, Bin, Janjigian, Yelena Y, Mellinghoff, Ingo K, Diaz, Luis A, Levine, Ross L, Abou-Alfa, Ghassan K, Stein, Eytan M, Intlekofer, Andrew M

Volltext

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score ma... von Botton, Stéphane, Brandwein, Joseph M., Wei, Andrew H., Pigneux, Arnaud, Quesnel, Bruno, Thomas, Xavier, Legrand, Ollivier, Recher, Christian, Chantepie, Sylvain, Hunault‐Berger, Mathilde, Boissel, Nicolas, Nehme, Salem A., Frattini, Mark G., Tosolini, Alessandra, Marion‐Gallois, Roland, Wang, Jixian J., Cameron, Chris, Siddiqui, Muhaimen, Hutton, Brian, Milkovich, Gary, Stein, Eytan M.

Volltext

Human Mesothelial Cells Are Unusually Susceptible to Simian Virus 40-Mediated Transformation and Asbestos Cocarcinogenicity von Bocchetta, M, Di Resta, I, Powers, A, Fresco, R, Tosolini, A, Testa, J R, Pass, H I, Rizzo, P, Carbone, M

Volltext

SV40 infection induces telomerase activity in human mesothelial cells von FODDIS, Rudy, DE RIENZO, Assunta, TESTA, Joseph R, CARBONE, Michele, BROCCOLI, Dominique, BOCCHETTA, Maurizio, STEKALA, Elizabeth, RIZZO, Paola, TOSOLINI, Alessandra, GROBELNY, Jennifer V, JHANWAR, Suresh C, PASS, Harvey I

Volltext

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib von Stein, Eytan M., DiNardo, Courtney D., Fathi, Amir T., Pollyea, Daniel A., Stone, Richard M., Altman, Jessica K., Roboz, Gail J., Patel, Manish R., Collins, Robert, Flinn, Ian W., Sekeres, Mikkael A., Stein, Anthony S., Kantarjian, Hagop M., Levine, Ross L., Vyas, Paresh, MacBeth, Kyle J., Tosolini, Alessandra, VanOostendorp, Jason, Xu, Qiang, Gupta, Ira, Lila, Thomas, Risueno, Alberto, Yen, Katharine E., Wu, Bin, Attar, Eyal C., Tallman, Martin S., de Botton, Stéphane

Volltext

A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome von Kirschbaum, Mark, Gojo, Ivana, Goldberg, Stuart L., Bredeson, Christopher, Kujawski, Lisa A., Yang, Allen, Marks, Peter, Frankel, Paul, Sun, Xing, Tosolini, Alessandra, Eid, Joseph E., Lubiniecki, Gregory M., Issa, Jean‐Pierre

Volltext

Association of Minimal Residual Disease Negativity Rates With Progression Free Survival in Frontline Therapy Trials for Newly Diagnosed Multiple Myeloma: A Meta-analysis von Ficek, Joseph, Kalaitzaki, Eleftheria, Yuan, Shuai Sammy, Tosolini, Alessandra, Du, Ling, Kremer, Brandon E, Davy, Katherine, Zhou, Helen, Chen, Tai-Tsang

Volltext

Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial von Stein, Eytan M, Fathi, Amir T, DiNardo, Courtney D, Pollyea, Daniel A, Roboz, Gail J, Collins, Robert, Sekeres, Mikkael A, Stone, Richard M, Attar, Eyal C, Frattini, Mark G, Tosolini, Alessandra, Xu, Qiang, See, Wendy L, MacBeth, Kyle J, de Botton, Stéphane, Tallman, Martin S, Kantarjian, Hagop M

Volltext

Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin? von Popat, Rakesh, Badros, Ashraf Z., Kumar, Shaji, Rodríguez-Otero, Paula, Cohen, Adam D., Manier, Salomon, Voorhees, Peter M., Gay, Francesca, Rifkin, Robert M., Martin, Thomas, Chari, Ajai, Weisel, Katja, Farooq, Asim V., Jeng, Bennie H., Chng, Wee Joo, Lee, Hans C., Berdeja, Jesus, Jadhav, Vinay, Tosolini, Alessandra, Eliason, Laurie, Palumbo, Antonio, Dimopoulos, Meletios A., Lonial, Sagar, Trudel, Suzanne, Richardson, Paul G., Terpos, Evangelos

Volltext

A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies von Gupta, Shilpa, Argilés, Guillem, Munster, Pamela N, Hollebecque, Antoine, Dajani, Olav, Cheng, Jonathan D, Wang, Ruixue, Swift, Ann, Tosolini, Alessandra, Piha-Paul, Sarina A

Volltext

Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1 von Balsara, Binaifer R., Pei, Jianming, De Rienzo, Assunta, Simon, Daniela, Tosolini, Alessandra, Lu, You Yong, Shen, Fu-Min, Fan, Xianglin, Lin, Wen-Yao, Buetow, Kenneth H., London, W. Thomas, Testa, Joseph R.

Volltext

Continuing Enasidenib Treatment for Patients with Mutant- IDH2 (m IDH2) Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with Stable Disease May Result in Improved Survival... von Stein, Eytan M., Stone, Richard M., Pollyea, Daniel A., Roboz, Gail J., Altman, Jessica K., DiNardo, Courtney D., de Botton, Stephane, Tu, Nora, Swern, Arlene S., Tosolini, Alessandra, Gupta, Ira, Agresta, Samuel V., Fathi, Amir T.

Volltext

Enasidenib Monotherapy Is Effective and Well-Tolerated in Patients with Previously Untreated Mutant- IDH2 (m IDH2) Acute Myeloid Leukemia (AML) von Pollyea, Daniel A., Tallman, Martin S., De Botton, Stephane, DiNardo, Courtney D., Kantarjian, Hagop M., Collins, Robert H., Stein, Anthony S., Xu, Qiang, Tosolini, Alessandra, Gupta, Ira, Agresta, Samuel V., Stein, Eytan M.

Volltext

Comprehensive Genomic Analysis of IDH Inhibitor-Treated AML Samples Delineates Molecular Mechanisms of Differentiation and Heterogeneous Patterns of Acquired Resistance von Wang, Feng, Morita, Kiyomi, DiNardo, Courtney D., Patel, Keyur, MacBeth, Kyle, Tosolini, Alessandra, Frattini, Mark G., Matthews, Jairo, Little, Latasha, Gumbs, Curtis, Tippen, Samantha, Song, Xingzhi, Zhang, Jianhua, Thompson, Erika, Kadia, Tapan M., Garcia-Manero, Guillermo, Jabbour, Elias J., Ravandi, Farhad, Konopleva, Marina Y., Kantarjian, Hagop M., Futreal, Andrew, Takahashi, Koichi

Volltext

Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial von Gao, Yue, Fan, Bin, Le, Kha, Manyak, Erika, Yang, Hua, Yen, Katherine, Agresta, Sam, Attar, Eyal C., Chen, Jian, Xu, Qiang, Tosolini, Alessandra, Mei, Jay M., Thakurta, Anjan, Knight, Robert D., Li, Yan

Volltext

Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS) von Stein, Eytan M., Fathi, Amir T., DiNardo, Courtney D, Pollyea, Daniel A, Swords, Ronan T, Roboz, Gail J., Collins, Robert, Sekeres, Mikkael A., Stone, Richard M., Attar, Eyal C, Tosolini, Alessandra, Xu, Qiang, Amatangelo, Michael, Gupta, Ira, Knight, Robert D., De Botton, Stéphane, Tallman, Martin S., Kantarjian, Hagop M.

Volltext

Safety/efficacy of MK-8669 (ridaforolimus) plus MK-2206 (AKT inhibitor) in patients with advanced breast cancer with low RAS signature and PTEN deficient prostate cancer von Gupta, Shilpa, Munster, Pamela N., Hollebecque, Antoine, Argiles, Guillem, Dajani, Olav, Cheng, Jonathan D., Swift, Ann M., Tosolini, Alessandra, Piha-Paul, Sarina Anne

Volltext

Results of a phase I trial combining ridaforolimus (mTOR inhibitor) and MK-0752 (Notch inhibitor) in patients with advanced solid tumors von Piha-Paul, Sarina Anne, Munster, Pamela N., Hollebecque, Antoine, Argiles, Guillem, Dajani, Olav, Cheng, Jonathan D., Wang, Ruixue, Swift, Ann M., Tosolini, Alessandra, Gupta, Shilpa

Volltext